Branded

01/03/2011 - 4:17pm
Drug approvals low in 2010

This past year saw a lower-than-usual number of new drugs approved by the Food and Drug Administration, due in part to delays at the agency, according to published reports.

01/03/2011 - 3:34pm
New strength of Intelence gets regulatory approval

The Food and Drug Administration has approved an update to the label of a Johnson & Johnson drug for HIV, the company said Monday.

01/03/2011 - 11:05am
George W. Bush to deliver keynote speech at Armada summit

Former president George W. Bush will deliver the keynote speech at Armada Health Care’s seventh annual Armada Specialty Pharmacy Summit, the specialty pharmacy contracting organization said.

12/29/2010 - 8:48pm
FDA rejection of lower-dose Copaxone will likely ward off generic competition

Recent news that the FDA has rejected Teva's application for a new lower-dose version of multiple sclerosis drug Copaxone likely will hold off the emergence of a generic version of the drug.

12/23/2010 - 4:17pm
Cephalon appoints new CEO

Cephalon on Thursday appointed Kevin Buchi as CEO and a member of the company's board.

12/23/2010 - 12:49pm
FDA approves Watson oral contraceptive

The Food and Drug Administration has approved the first and only low-dose oral contraceptive to combine 0.8-mg norethindrone and 0.025-mg ethinyl estradiol in a chewable form, with four 75-mg ferrous fumarate (iron) placebo tablets, Watson Pharmaceuticals has announced.

12/23/2010 - 12:29pm
FDA approves Novartis drug for high blood pressure treatment

The Food and Drug Administration on Wednesday approved Novartis Pharmaceuticals’ Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets for the treatment of high blood pressure, according to the pharma company.

12/23/2010 - 12:25pm
FDA approves Merck's Gardasil for prevention of anal cancer

Merck on Wednesday announced that the Food and Drug Administration has approved Gardasil [human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant] for the prevention of anal cancer in males and females 9 to 26 years of age.

12/22/2010 - 11:14am
Takeda settles patent suits relating to Actos

Takeda and its subsidiary settled the patent suits it brought against generic drug makers that sought to develop their own versions of its diabetes treatment.

12/21/2010 - 5:30pm
Biogen acquires rights to neuro disease programs

In a deal that will bolster its drug development capabilities, Biogen Idec has acquired a subsidiary of Swiss-based Neurimmune Holding AG.

© 2013 Drug Store News. All Rights Reserved.